To the full analysis
Valerio Therapeutics stock: Returns and Performance
ALVIO.PAValerio Therapeutics's share price rose by 211.3% over the last year.
This shows what Valerio Therapeutics S.A. has returned on the stock market in the past. Past returns say nothing about the future.
1 year
+211.3%
since 12 Nov 2025
3 years
+35.9%
a year, +151% in total
Returns by period
| Period | Total | Per year |
|---|---|---|
| 1 year | +211.3% | +211.3% |
| 3 years | +151% | +35.9% |
Returns by calendar year
Figures as a table
| Year | Return |
|---|---|
| 2026 to date | +228.3% |
| 2025 | +84% |
| 2024 | −54.5% |
Peak price and largest drawdown
All-time high
$0.97
on 21 Jul 2026, today 48.4% below
Largest drawdown
−86.7%
from the high on 30 Aug 2023 to the low on 10 Feb 2025, regained on 2 Jul 2026
This is the pure share price return in euros from closing prices, adjusted for stock splits. Dividends come on top and are not included here.
Work out your own amount and period in the What-if calculatorData status and sources
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 May 2024)
- Valuation signal Overvalued since 10 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.